Biologically Inspired Engineering, synbio, synthetic biology, crispr
Brad Loncar, Founder of BiotechTV, observed during an interview in October 2023 that some people were dressed as GLP-1 agonists for Halloween. He was interviewing Dr. Eric Topol, of Scripps Research Institute, who suggested they dress up as skeletons due to how little is known about the mode of action in this class of drugs … Read more
According to Persistence Market Research, the global bladder cancer treatment drugs market reached a size of $2bn in 2021 and is estimated to surge to $11.5bn by 2032, advancing at a 17% CAGR from 2022 to 2032. Two companies targeting high-risk non-muscle invasive bladder cancer (NMIBC) are nearing approval of drugs that show great promise. … Read more
Investment banking giant Goldman Sachs is making a major move into the life sciences sector with the launch of its first-ever dedicated fund, West Street Life Sciences I. The $650 million fund signals Goldman’s confidence in the burgeoning field and its potential for significant returns despite a recent period of setback and gloom – and … Read more
U.S. pharmaceutical companies Moderna and Merck say a clinical trial for an experimental Moderna mRNA vaccine used in combination with the Merck cancer therapy drug Keytruda reduced the chance of recurrence or death from melanoma by nearly 50%. “As we continue to follow participants in the KEYNOTE-942/mRNA-4157-P201 study, we are excited to see such a … Read more
CG Oncology is a biotech company focused on developing innovative treatments for bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Their two main clinical programs involve cretostimogene grenadenorepvec (CG0070), an oncolytic immunotherapy. CG Oncology filed confidentially on October 27, 2023. The company filed publicly this week with the SEC to raise up to $100 million … Read more
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. The company’s approach involves the direct injection into tumors of a unique product created from its DfuseRx℠ discovery platform. Valuation/risk: According to Stifel, Phase 3 valuations are up 33% since … Read more
The field of gene editing has taken a leap forward with the recent approvals of two CRISPR-based drugs, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD). These groundbreaking therapies offer potential for treating this previously incurable disease, generating excitement and hope for patients and the science around gene editing. The Money Pricing: … Read more
Ohalo Genetics is dedicated to accelerating the evolution of crops to create more efficient and sustainable agriculture. They use innovative plant genetic technologies to improve various aspects of crops, including: Yield: They aim to increase crop yields to meet the growing demand for food from a world population that is expected to reach 10 billion … Read more
Google Cloud recently announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and … Read more
Earlier this year, a Jefferies analyst quantified the market downturn in the biotechnology sector and came up with a number: 128 companies were trading at a market cap smaller than the cash they have on hand, representing 25% share. This rivals the severity of 2008-2009 period, where 15-20% of the industry was trading below cash. … Read more